Pharma Industry News

Novo Nordisk oral diabetes drug outperforms Lilly rival

The company's oral diabetes drug semaglutide was found to be better at lowering blood sugar levels than Jardiance from Eli Lilly and Boehringer IngelheimOriginal Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]